Applied Therapeutics secures FDA meeting this fall on its plan to submit govorestat for CMT-SORD. And what’s this about a free SORD test?
This Genetic Tape Could Silence the Cause of CMT2E
What happened when CMTA-supported scientists at the University of Miami applied a piece of genetic tape to the gene mutation that causes CMT2E?
CMTA Announces Its Newest Center of Excellence: Charleston, SC
A new CMTA Center of Excellence has landed in Charleston. Meet the team bringing expert CMT care to South Carolina and connect with them today.
What If We Could Measure CMT4J Getting Worse Before It Feels Worse?
Tracking CMT4J from the Inside Out: What MRI Scans Are Showing So Far With CMTA...
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA-STAR Alliance Partner Doses First CMT2S Patient
What 50 People Taught Us about CMT1E Progression and Genetics
A new study, powered by the CMTA-INC Alliance, offers answers. By analyzing data from 50 people with PMP22 variants, researchers linked specific mutations to age of onset, symptom severity, and progression—laying the groundwork for better care and trial design.
CMTA Announces New Center of Excellence at UC Davis Health
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is...
CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types
What happens when the world’s largest CMT funder joins forces with the leading clinical research network? A new era begins. Inside: the alliance changing everything.
Augustine Therapeutics Begins New CMT Trial
CMT news out of Belgium: Augustine Therapeutics has officially dosed the first participant in a...
CMTA Presents New Genetic Landscape Analysis at The 2025 Annual Meeting of the Peripheral Nerve Society
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research, presented a...
